Table 2.
Experimental groupsa | % viable CD3+ | % CD3+CD4+ | % CD3+CD8+ | CD3+CD4+/CD3+CD8+ |
---|---|---|---|---|
DMSO/SAL–PBS | 0.2 | 36 | 11.8 | 3.1 |
DMSO/SAL–hASC | 5.4 | 28.6 | 50.5 | 0.6 |
AP/AP–PBS | 0.5 | 44.9 | 21.4 | 2.1 |
AP/AP–hASC | 8.8 | 29.9 | 48.5 | 0.6 |
The percentage of the different lymphocyte subpopulations in the pooled BALFs from 10 mice per group receiving an intravenous injection of 1×106 hASCs or PBS was assessed 6 days later by flow cytometry with CD-specific antibodies.
BALF, bronchoalveolar lavage fluid.